The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
Open accessAbstract
This open-label, phase I/II study investigated the safety and efficacy of epratuzumab, a humanised anti-CD22 monoclonal antibody, in the treatment of patients with active primary Sjögren's syndrome (pSS). Sixteen Caucasian patients (14 females/2 males, 33–72 years) were to receive 4 infusions of 360 mg/m 2 epratuzumab once every 2 weeks, with 6 months of follow-up. A composite endpoint involving the Schirmer-I test, unstimulated whole salivary flow, fatigue, erythrocyte sedimentation rate (ESR), and immunoglobulin G (IgG) was devised to provide a clinically meaningful assessment of response, defined as a ≥20% improvement in at least two of the aforementioned parameters, with ≥20% reduction in ESR and/or IgG considered as a single combined criterion. Fourteen patients received all infusions without significant reactions, 1 patient received 3, and another was discontinued due to a mild acute reaction after receiving a partial infusion. Three patients showed moderately elevated levels of Human anti-human (epratuzumab) antibody not associated with clinical manifestations. B-cell levels had mean reductions of 54% and 39% at 6 and 18 weeks, respectively, but T-cell levels, immunoglobulins, and routine safety laboratory tests did not change significantly. Fifty-three percent achieved a clinical response (at ≥20% improvement level) at 6 weeks, with 53%, 47%, and 67% responding at 10, 18, and 32 weeks, respectively. Approximately 40%–50% responded at the ≥30% level, while 10%–45% responded at the ≥50% level for 10–32 weeks. Additionally, statistically significant improvements were observed in fatigue, and patient and physician global assessments. Further, we determined that pSS patients have a CD22 over-expression in their peripheral B cells, which was downregulated by epratuzumab for at least 12 weeks after the therapy. Thus, epratuzumab appears to be a promising therapy in active pSS, suggesting that further studies be conducted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H. M., Alexander, E. L., Carsons, S. E., Daniels, T. E., Fox, P. C., Fox, R. I., Kassan, S. S., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.6.554 · Cited by 5,299
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
NAVAZESH, M. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb18343.x · Cited by 1,445
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study
Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21260 · Cited by 500
Salomonsson, S., Jonsson, M. V., Skarstein, K., Brokstad, K. A., Hjelmström, P., Wahren‐Herlenius, M., & Jonsson, R. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11311 · Cited by 472
Sato, S., Miller, A. S., Inaoki, M., Bock, C. B., Jansen, P. J., Tang, M. L. K., & Tedder, T. F. (1996) · Immunity · doi:10.1016/s1074-7613(00)80270-8 · Cited by 434
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Gottenberg, J.-E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029694 · Cited by 401
Stott, D. I., Hiepe, F., Hummel, M., Steinhauser, G., & Berek, C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3234 · Cited by 335
Bohnhorst, J. Ø., Bjørgan, M. B., Thoen, J. E., Natvig, J. B., & Thompson, K. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.3610 · Cited by 321
O'Keefe, T. L., Williams, G. T., Batista, F. D., & Neuberger, M. S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1307 · Cited by 320
Dörner, T., Kaufmann, J., Wegener, W. A., Teoh, N., Goldenberg, D. M., & Burmester, G. R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1942 · Cited by 306
Self-citationHansen, A., Odendahl, M., Reiter, K., Jacobi, A. M., Feist, E., Scholze, J., Burmester, G. R., Lipsky, P. E., & Dörner, T. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10445 · Cited by 271
Self-citationPhase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma
Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Ely, S., Furman, R. R., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.082 · Cited by 253
Self-citationBowman, S., Ibrahim, G., Holmes, G., Hamburger, J., & Ainsworth, Jr. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740310004676 · Cited by 216
The role of CD22 and other inhibitory co-receptors in B-cell activation
Nitschke, L. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.03.005 · Cited by 193
CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction
Tedder, T. F., Poe, J. C., & Haas, K. M. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(05)88001-0 · Cited by 185
Carnahan, J. F., Wang, P., Kendall, R. L., Chen, C., Hu, S., Boone, T., Juan, T., Talvenheimo, J., Montestruque, S., Sun, J., et al. (2003) · PubMed · Cited by 185
Carnahan, J., Stein, R., Qu, Z., Hess, K., Cesano, A., Hansen, H. J., & Goldenberg, D. M. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.05.007 · Cited by 175
Self-citationStein, R., Qu, Z., Chen, S., Rosario, A., Shi, V., Hayes, M., Horak, I. D., Hansen, H. J., & Goldenberg, D. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0493 · Cited by 171
Self-citationEngel, P., Nojima, Y., Rothstein, D., Zhou, L. J., Wilson, G. L., Kehrl, J. H., & Tedder, T. F. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.11.4719 · Cited by 167
The effect of moderate alcohol consumption on bone mineral density: a study of female twins
Williams, F. M. K., Cherkas, L. F., Spector, T. D., & MacGregor, A. J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.022269 · Cited by 83
Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2
Stein, R., Belisle, E. H., Hansen, H. J., & Goldenberg, D. M. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01518451 · Cited by 76
Self-citationNew prospects for autoimmune disease therapy: B cells on deathwatch
Clair, E. W. S., & Tedder, T. F. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21525 · Cited by 35
Cited by
Brito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Sivils, K., Theander, E., Tzioufas, A., & Ramos-Casals, M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.47 · Cited by 868
EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies
Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., Bootsma, H., De Vita, S., Dörner, T., Fisher, B. A., Gottenberg, J.-E., Hernandez-Molina, G., Kocher, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216114 · Cited by 732
Treatment of Primary Sjögren Syndrome: A Systematic Review
Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Sisó, A., & Bosch, X. (2010) · JAMA · doi:10.1001/jama.2010.1014 · Cited by 381
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome
Xu, J., Wang, D., Liu, D., Fan, Z., Zhang, H., Liu, O., Ding, G., Gao, R., Zhang, C., Ding, Y., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391144 · Cited by 315
Advances in Human B Cell Phenotypic Profiling
Kaminski, D. A., Wei, C., Qian, Y., Rosenberg, A. F., & Sanz, I. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00302 · Cited by 272
Metadata
- Authors
- Steinfeld, S. D., Tant, L., Burmester, G. R., Teoh, N. K., Wegener, W. A., Goldenberg, D. M., & Pradier, O.
- Venue
- Arthritis Research & Therapy
- Published
- 2006-07-20
- Volume
- 8
- Issue
- 4
- Pages
- R129-R129
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2134085268
- Cited by
- 258
- References
- 26
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.